NEU² Partners: Baliopharm
Baliopharm AG is a biotechnology company focusing on the development of novel therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis, Crohn`s disease, psoriasis and multiple sclerosis, and for cancer. The company was founded in 2011 as a spin-off of Celonic AG, a service provider in the area of contract manufacturing and contract analysis operating since 1998. Since 2007, Celonic AG was also developing their own therapeutic proteins targeting cancer and immune-mediated diseases.
Baliopharm AG is focusing on the further preclinical and clinical development of these therapeutic proteins as well as on newly inlicensed compounds.
Baliopharm AG is located in Basel (Switzerland), with a subsidiary in Jülich (Baliopharm GmbH, Germany).